Latest Information Update: 18 Jul 2007
At a glance
- Originator Matrix Therapeutics
- Class Anaesthetics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Anaesthesia
Most Recent Events
- 25 Feb 2003 No development reported - Phase-II for Anaesthesia in United Kingdom (unspecified route)
- 05 Nov 2001 Phase-II clinical trials for Anaesthesia in United Kingdom (Unknown route)